Local Collaborations
Information Box Group
Dr. Rick Austin
(HKRC)
- Assessment of ER stress and UPR in experimental systems
- GRP78 HET transgenic mice
Dr. Gerard Cox
(FIRH)
- Clinical collaborator, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (COPD)
Dr. Jean-Claude Cutz
(Department of Pathology and Molecular Medicine)
- Molecular and clinical pathology
- Assessment of lung histology
- Tissue microarrays (TMA’s)
Dr. Jeffrey G Dickhout
(HKRC)
- Assessment of ER stress and UPR in experimental systems
- Experimental in vitro systems
Dr. Troy Farncombe
(SAIC)
- Imaging
Dr. Nathan Hambly
(FIRH)
(PULMONARY RESEARCH REGISTRY)
- Identification of patients with chronic lung disease
Dr. Mark D Inman
(FIRH)
- Assessment of pulmonary function in experimental models
- Scientific artist
- Biostatistics
Dr. Martin RJ Kolb
(FIRH)
- Clinical collaborator, idiopathic pulmonary fibrosis
- Therapeutic intervention, experimental models of pulmonary fibrosis
Dr. Renee N. Labiris
(FIRH, SAIC)
- Imaging
- Automatic assessment of air-space enlargement in experimental models
Dr. Param Nair
(FIRH)
- Assessment of inflammation in patients with chronic respiratory disease
- Clinical collaborator, chronic obstructive pulmonary disease (COPD)
Dr. Asghar Naqvi
(Department of Pathology and Molecular Medicine)
- Molecular and clinical pathology
- Assessment of lung histology
- Tissue microarrays (TMA’s)
Dr. Carl Richards
(MIRC)
- Experimental models of lung cancer
- Cytokine biology
- Imaging
Dr. Martin R Stämpfli
(MIRC-FIRH)
- Cigarette smoke exposure system
- Assessment of lung inflammation
International Collaborations
Information Box Group
Dr. Souheil El-Chemaly
(Brigham, MA, USA)
• Experimental models of pulmonary fibrosis
• Lymphatics
Dr. Souheil El-Chemaly
(Brigham, MA, USA)
• Experimental models of pulmonary fibrosis
• Lymphatics
Dr. Jørn A Holme
(Folkehelsa, Oslo, Norway)
• Role of the UPR in nitropyrene (pollutant) cell toxicity
Dr. Jørn A Holme
(Folkehelsa, Oslo, Norway)
• Role of the UPR in nitropyrene (pollutant) cell toxicity
Dr. Joel Moss
(NHLBI. NIH, MD, USA)
• BIG1-FKBP13 interaction
• FKBP13 deficient mice
Dr. Joel Moss
(NHLBI. NIH, MD, USA)
• BIG1-FKBP13 interaction
• FKBP13 deficient mice
Dr. Martha Vaughan
(NHLBI. NIH, MD, USA)
• BIG1-FKBP13 interaction
• FKBP13 deficient mice
Dr. Martha Vaughan
(NHLBI. NIH, MD, USA)
• BIG1-FKBP13 interaction
• FKBP13 deficient mice
Dr. Souheil El-Chemaly
(Brigham, MA, USA)
• Experimental models of pulmonary fibrosis
• Lymphatics
Dr. Souheil El-Chemaly
(Brigham, MA, USA)
• Experimental models of pulmonary fibrosis
• Lymphatics
Dr. Jørn A Holme
(Folkehelsa, Oslo, Norway)
• Role of the UPR in nitropyrene (pollutant) cell toxicity
Dr. Jørn A Holme
(Folkehelsa, Oslo, Norway)
• Role of the UPR in nitropyrene (pollutant) cell toxicity
Dr. Joel Moss
(NHLBI. NIH, MD, USA)
• BIG1-FKBP13 interaction
• FKBP13 deficient mice
Dr. Joel Moss
(NHLBI. NIH, MD, USA)
• BIG1-FKBP13 interaction
• FKBP13 deficient mice
Dr. Martha Vaughan
(NHLBI. NIH, MD, USA)
• BIG1-FKBP13 interaction
• FKBP13 deficient mice
Dr. Martha Vaughan
(NHLBI. NIH, MD, USA)
• BIG1-FKBP13 interaction
• FKBP13 deficient mice